Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs in R&D
Published in: Drugs in R&D 3/2017

Open Access 01-09-2017 | Original Research Article

A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis

Authors: Koichiro Homma, Joe Yoshizawa, Yutaka Shiina, Hideki Ozawa, Muneki Igarashi, Tadashi Matsuoka, Junichi Sasaki, Mamoru Yoshizawa, Yasuhiko Homma

Published in: Drugs in R&D | Issue 3/2017

Login to get access

Abstract

Objective

A high plasma level of remnant-like particle cholesterol (RLP-C), which is equivalent to triglyceride-rich lipoprotein remnant, is an important coronary risk marker. RLP-C level is high, independent of other plasma lipids, in patients with chronic kidney disease (CKD) undergoing hemodialysis. The effect of teneligliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, on plasma levels of RLP-C in patients with diabetes mellitus and CKD under hemodialysis was studied.

Methods

Teneligliptin 20 mg/day was administered to 15 patients with diabetes and CKD undergoing hemodialysis for 12 weeks. Ten patients with diabetes and CKD undergoing hemodialysis were allocated to the control group. Blood was sampled following a 12-h fast. Fasting plasma glucose (FPG), C-peptide, triglyceride, low-density lipoprotein (LDL)-cholesterol (C), high-density lipoprotein (HDL)-C, RLP-C, apolipoprotein (apo) B, oxidized LDL, lipoprotein lipase, and glycated hemoglobin (HbA1c) were measured.

Results

HbA1c decreased in the teneligliptin group but significantly increased in the control group. FPG and RLP-C significantly decreased in the teneligliptin group. Plasma lipoprotein-related parameters except RLP-C were not affected by teneligliptin treatment.

Conclusion

Teneligliptin treatment significantly reduced plasma levels of RLP-C, FPG, and HbA1c in patients with diabetes with CKD who are undergoing hemodialysis.
Literature
1.
Dicker D. DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors. Diabetic Care. 2011;34(Suppl 2):s276–8.CrossRef
2.
Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7–18.CrossRefPubMed
3.
Kutoh E, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug naïve subjects with type 2 diabetes. J Clin Med Res. 2014;6:287–94.PubMedPubMedCentral
4.
Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987;28:613–28.PubMed
5.
Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabet Care. 2004;27:1496–504.CrossRef
6.
Williams K, Tchermof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes. 2008;57:3289–96.CrossRefPubMedPubMedCentral
7.
8.
Kwan BCK, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–61.CrossRefPubMed
9.
Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. In: Scriver SPR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 2705–16.
10.
Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoprotein isolated from human plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992;33:369–80.PubMed
11.
Campos E, Kotite I, Blanche P, Mitsugi Y, Frost PH, Masharani U, et al. Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood. J Lipid Res. 2002;43:365–74.PubMed
12.
Twickler TB, Dalinga-Thie GM, Cohn JD, Chapman MJ. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation. 2004;109:1918–25.CrossRefPubMed
13.
Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36–47.CrossRefPubMed
14.
Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med. 1982;307:329–33.CrossRefPubMed
15.
Ron D, Oren I, Aviram M, Better OS, Brook JG. Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis. 1983;46:67–75.CrossRefPubMed
16.
Oda H, Yoshioka N, Nishda Y, Nishida Y, Kushihata S, Ito T, et al. Remnant-like particle cholesterol indicate atherogenic risk in patients on chronic hemodialysis. Nephron. 1997;76:7–14.CrossRefPubMed
17.
Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, et al. Remarkable increase of apolipoprotein B-48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 2008;197:154–8.CrossRefPubMed
18.
Homma K, Homma Y, Yamaguchi Y, Shiina Y, Wakino S, Hayashi K, et al. Triglyceride-rich lipoproteins in chronic kidney disease patients undergoing maintenance hemodialysis treatment. Int J Clin Pract. 2012;66:394–8.CrossRefPubMed
19.
Witstum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–92.CrossRef
20.
Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscl Thromb Vasc Biol. 2000;20:2243–7.CrossRefPubMed
21.
Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–60.CrossRefPubMed
22.
Holvoert P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly. Findings from the health, aging, and body composition. Arterioscler Thromb Vasc Biol. 2003;23:1444–8.CrossRef
23.
Knowles WJ, Haigh WB, Michaud GC. A monoclonal antibody-based immunoassay for hemoglobin A1c. Diabetes. 1986;35(Suppl 1):94A.
24.
Kao PC, Robert L, Taylor BS, et al. C-peptide immunochemiluminometric assay developed from two seemingly identical polyclonal antisera. Ann Clin Lab Sci. 1992;22:307–16.PubMed
25.
Noma A, Hata Y, Goto Y, et al. Quantification of serum apolipoprotein A-I, B, C-II, C-III, and E by turbidimetric immunoassay: reference values, age-, sex-related differences. Clin Chim Acta. 1991;199:147–58.CrossRefPubMed
26.
Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti-apo Ai and apo B immunoaffinity mixed gel. Clin Chim Acta. 1993;223:53–71.CrossRefPubMed
27.
Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta. 1994;1215:121–5.CrossRefPubMed
28.
Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis. 1999;145:45–50.CrossRefPubMed
29.
Brunzell J, Deeb SS. Familial lipoprotein lipase deficiency, Aoc C-II deficiency, and hepatic lipase deficiency. In: Scriver SPR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 2789–815.
30.
Kutoh H, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug naïve subjects with type 2 diabetes. J Clin Res. 2014;6:287–94.
31.
Kusunoki M, Sato D, Nakamura T, et al. DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes. Drug Res. 2015;65:532–624.
32.
33.
Homma K, Homma Y, Shiina Y, Kanda T, Tokuyama H, Wakino S, et al. Plasma levels of coronary risk biomarkers in chronic kidney disease patients undergoing maintenance hemodialysis treatment. J Endocrinol Diabetes Obes. 2014;2:1020–3.
Metadata
Title
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
Authors
Koichiro Homma
Joe Yoshizawa
Yutaka Shiina
Hideki Ozawa
Muneki Igarashi
Tadashi Matsuoka
Junichi Sasaki
Mamoru Yoshizawa
Yasuhiko Homma
Publication date
01-09-2017
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 3/2017
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.1007/s40268-017-0189-5

Other articles of this Issue 3/2017

Drugs in R&D 3/2017 Go to the issue

Original Research Article

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Original Research Article

A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation

Original Research Article

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

Original Research Article

Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study

Original Research Article

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

Short Communication

Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study